SLDB News
Archived Headlines
- Solid Biosciences increases proposed deal size to $130 million ahead of tonight's IPO 01/24/18
- US IPO Week Ahead: 10 IPOs expected to price, led by PagSeguro's $1.8 billion deal 01/19/18
- Gene therapy biotech Solid Biosciences sets terms for $100 million IPO 01/16/18
- US IPO Week Ahead: ADT looks to secure $2 billion in 3-IPO week 01/12/18
- US IPO Weekly Recap: no IPOs during holiday week 12/29/17
See more
Pushing preclinical: Wave of early-stage biotech IPOs tests investor risk appetite
Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018,...read more
Biotechs take the podium with the year's 3 best IPOs
Biotechs hold gold, silver and bronze in the 2018 IPO market. Cancer immunotherapy devloper ARMO BioSciences (ARMO) is by far the year's best-performing IPO, up 200% from its offer price. Rounding out the podium is chronic itch biotech...read more
US IPO Week Ahead: Look for a wave of filings in a quiet holiday week with 2 IPOs
Two small deals are on the calendar for the holiday week ahead, including single-asset Reg A+ IPO Aspen REIT and blank check company Crescent Funding. We expect IPO filing activity to pick up as we move...read more
Solid Biosciences prices $124.8 million IPO at $16, below the revised range
Solid Biosciences, which is developing a gene therapy to treat Duchenne muscular dystrophy (DMD), raised $124.8 million by offering 7.8 million shares at $16, below the revised range of $18 to $19. Insiders purchased $40 million of the IPO (32% of deal size). At...read more